George L. McLendon, PhD
Dr. McLendon is a founder of TetraLogic Corporation and co-Chairman of the scientific advisory board.  Presently Dr. McLendon is the Dean of the College or Arts and Sciences at Duke University.  Dr. McLendon was formerly the Russell Wellman Moore Professor of Chemistry and Chairman of the Department of Chemistry at Princeton University. Prior to Princeton University, he was the Tracy H. Harris Professor of Chemistry and Chair, Department of Chemistry at the University of Rochester. Dr. McLendon has lectured and published extensively; and has received numerous awards and honors including Academy of Distinguished Graduate Award, American Chemical Society Akron Section Award, American Chemical Society Eli Lilly Award in Biological Chemistry and the American Chemical Society Pure Chemistry Award. Dr. McLendon received his Ph.D. in inorganic chemistry at Texas A&M University.

Yigong Shi, PhD
Dr. Shi is a founder of TetraLogic and co-Chairman of the company’s scientific advisory board.  Dr.  Shi is Professor, Department of Molecular Biology at Princeton University and has been at Princeton since 1998.  Prior to 1998, Dr. Shi was a postdoctoral fellow in the Structural Biology Laboratory of Tumor Suppressors and Oncogenes at the Memorial Sloan-Kettering Cancer Center and in the Department of Biophysics and Biophysical Chemistry at the Johns Hopkins School of Medicine.  Dr. Shi’s research is aimed at understanding the structural and molecular mechanisms involved in tumorigenesis, with a focus on key regulatory components in the Apoptotic pathways.  Dr. Shi received is undergraduate degrees biology and mathematics at Tsinghua University, Beijing, China and his Ph.D. in Molecular Biophysics at Johns Hopkins University.  

David Vaux, PhD
Dr. Vaux is a Federation Fellow in the Department of Biochemistry, LaTrobe University, Victoria, Australia.  Dr. Vaux is a recognized leader in the area of apoptosis. The link between apoptosis and cancer was established by Dr. Vaux and colleagues in 1988 with the discovery that the bcl-2 gene specifically blocks death of B cells in follicular lymphoma (an immune system cancer).  Dr. Vaux is also credited with the discovery with DIABLO or SMAC and its role in relieving caspase inhibition through its binding to XIAP.  Dr. Vaux received a BMedSci and MBBS (equivalent of US MD) from the University of Melbourne, and a Ph.D. from The Walter and Eliza Hall Institute (WEHI), Melbourne, Australia.

Peter O’Dwyer, MD
Dr. O’Dwyer received an M.B., B.Ch at the University of Dublin, Trinity College.  After residencies in pediatrics and internal medicine, he was a Fellow at the Baltimore Cancer Research Center, and then a Senior Investigator at the Investigational Drug Branch, Cancer Therapy Evaluation Program, of the National Cancer Institute. Dr. O’Dwyer is presently Professor of Medicine at the University of Pennsylvania, and Director of the Experimental Therapeutics Program in the Abramson Cancer Center of the University of Pennsylvania.  He is Vice Chairman of the Eastern Cooperative Oncology Group and co-Chair of the Gastrointestinal Committee. Dr. O’Dwyer has extensive clinical experience with the chemotherapy of colorectal cancer and with antiangiogenesis therapies.

Robert K. Lynn, PhD
Dr. Lynn is an independent consultant that provides consultation in preclinical development.  He was the former Senior Vice President of Preclinical Development at GlaxoSmithKline Pharmaceuticals where he had over 24 years of pharmaceutical drug metabolism and preclinical development leadership experience.  Dr. Lynn received a B.A. in Chemistry from Murray State University, and a Ph.D. in Medicinal Chemistry from Australian National University, Canberra, Australia.

Randall Johnson, PhD
Dr. Johnson is an independent consultant that provides consultation in oncology drug discovery and development.  He formerly directed oncology discovery at SmithKline Beecham Pharmaceuticals.  Dr. Johnson has over 30 years of experience in government and industry working in cancer drug discovery/development and screening technologies. He worked at the National Cancer Institute, NIH, Bethesda as Section Head, Laboratories of Experimental Chemotherapy and Chemical Pharmacology before joining the pharmaceutical industry.  Dr. Johnson received a B.Sc. in Biochemistry from the University of Minnesota, and a Ph.D. in Pharmacology from George Washington University.

Mrs. William McCormick Blair, Jr.
Mrs. Blair serves as Secretary and Director of the Foundation for the National Institutes of Health, Co-Chair of the Harvard Aid Initiative International Advisory Council and is on the Board of Scripps Research Institute. She is Vice president and Director Emeritus of the Albert and Mary Lasker Foundation and worked closely with Mrs. Lasker on the Conquest of Cancer, the National High Blood Pressure Campaign, and the Lasker Awards. She is a member of a variety of organizations focused on biomedical research and advocacy, including the Harvard Medical School Department of Microbiology and Molecular Genetics, and the New York Center for Autism. Previously, she served on the Board of the American Cancer Society and the Breast Cancer Task force of the National Cancer Institute, and the Rockefeller University Council. Mrs. Blair’s professional career has included consultancies with Novartis and HealthCare Ventures, LLC, as well as a variety of life sciences companies such as Genetic Therapy Inc, MedImmune, Human Genome Sciences, Biotransplant, PharmAthene, and Ingenuity among others.